Oxxon’s proprietary PrimeBoost platform is an approach that allows rapid development of products to selectively stimulate and enhance a potent cellular response.
The recent phase II study showed PrimeBoost’s potential to produce an immune response in patients and evidence of an anti-tumor response. The treatment was also seen to be safe and well-tolerated.
In this study, 25% of the stage III and IV patients enrolled were stable up to week 16. In addition, one stage III patient showed a partial clinical response which was sustained up to week 72 following further MVA boosting. This patient also showed a striking immunological response.
Overall, 29% of the immunologically evaluable patients showed melanoma-specific cellular immune responses. Three of these patients (10%) showed a T-cell response to more than one epitope. Interestingly, all stage III melanoma patients showed a confirmed immunological response.
“These data continue to support PrimeBoost’s ability to elicit a melanoma-specific immune response and support future development of the current melanoma immunotherapeutics, particularly in stage III patients,” said Dr Deirdre Gillespie, CEO at Oxxon.